GBI Research estimated the travel vaccines market in the top seven markets (comprising the US, the UK, Spain, Italy, France, Germany and Japan) to be worth $1,343m in 2012, having grown at a Compound Annual Growth Rate (CAGR) of 11% from 2007. The Year-on-Year (YoY) market growth was 6.3%, with revenue of $1,264m in 2011. It is expected to reach $2,224m by 2019, having grown at a CAGR of 7.5% from 2012.

The hepatitis A travel vaccines market in the top seven markets was worth $264m in 2012 and is expected to reach $423m by 2019 at a CAGR of 7%. The meningococcal travel vaccines market accounted for $225m in 2012 and is expected to reach $406m by 2019 at a CAGR of 8.8%. The Japanese Encephalitis (JE) travel vaccines market accounted for $234m in 2012 and is expected to reach $283m by 2019 at a CAGR of 2.7%.

A Strong Pipeline in which Nearly 30% of Vaccine Candidates are in Phase III and Phase II

The global travel-vaccine pipeline appears very strong, with 18% of candidates in Phase II, 13% in Phase I, 11% in Phase III and 5% registration-filed.

Vaccine companies manage their R&D portfolio by balancing investment between novel, innovative targets with the potential to have a major impact on human health; developing best-in-class approaches; and delivering the maximum value of approved vaccines through new indications and formulations. Developing a new vaccine product is a costly, lengthy and uncertain process, and a new candidate can fail at any stage of the development process or fail to receive regulatory approval. However, vaccines’ ability to generate high revenues and profits despite being priced at a premium has proven attractive to existing players in the market and to big pharmaceutical companies, who have been watching development with interest.

Hepatitis A Vaccines, Japanese Encephalitis Vaccines and Meningococcal Vaccines Account for More than Half of the Market

Hepatitis A vaccines led the market in 2012 with a share of 20%, followed by JE vaccines and meningococcal vaccines with 17% each.

Hepatitis A vaccines are commonly used prominent travel vaccines, and the increase in global tourist traffic has increased their use, in turn driving the market. Vaccines for hepatitis A provide immunity for approximately 15–20 years, rather than being lifelong, which is expected to drive future growth.